Key result
Survivors of paralytic and non-paralytic poliomyelitis had increased lifelong mortality compared with matched controls (HR 1.31, 95% CI 1.18-1.44 and HR 1.09, 95% CI 1.00-1.19, respectively).
Why the study?
Does a history of poliomyelitis increase lifelong morbidity and mortality compared to matched controls?
Cohort (n=17,368)
Does a history of poliomyelitis increase lifelong morbidity and mortality compared to matched controls?
Hazard Ratio: 1.31 (95% CI 1.18–1.44)
Poliomyelitis survivors experience significantly increased lifelong mortality and morbidity compared to matched controls.
Supports clinical vigilance for excess mortality in polio survivors; leaves open causal pathways and intervention targets.
BACKGROUND AND PURPOSE: In the world today 10-20 million people are still living with late effects of poliomyelitis (PM), but the long-term consequences of the disease are not well known. The aim of this study was to describe lifelong morbidity and mortality among Danes who survived PM. METHODS: Data from official registers for a cohort of 3606 Danes hospitalized for PM in the period 1940-1954 were compared with 13 762 age- and gender-matched controls. RESULTS: Compared with controls, mortality was moderately increased for both paralytic as well as non-paralytic PM cases; Hazard Ratio, 1.31 (95% confidence interval, 1.18-1.44) and 1.09 (95% confidence interval, 1.00-1.19), respectively. Hospitalization rates were approximately 1.5 times higher among both paralytic and non-paralytic PM cases as compared with controls. Discharge diagnoses showed a broad spectrum of diseases. There were no major differences in morbidities between paralytic and non-paralytic PM cases. CONCLUSIONS: Poliomyelitis has significant long-term consequences on morbidity and mortality of both paralytic and non-paralytic cases.
No takes yet. Share an insight, caveat, or question.
Kay et al. (2016) conducted a cohort in Poliomyelitis (n=17,368). Poliomyelitis vs. Age- and gender-matched controls was evaluated on Mortality (HR 1.31, 95% CI 1.18-1.44). Survivors of paralytic and non-paralytic poliomyelitis had increased lifelong mortality compared with matched controls (HR 1.31, 95% CI 1.18-1.44 and HR 1.09, 95% CI 1.00-1.19, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: